JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB267048

Human TDRD7 knockout A549 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

TDRD7 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 8 and 2 bp deletion in exon 8 and 2 bp insertion in exon 8. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
4 Images
Sanger Sequencing - Human TDRD7 knockout A549 cell line (AB267048)
  • Sanger seq

Unknown

Sanger Sequencing - Human TDRD7 knockout A549 cell line (AB267048)

Allele-1 : 2 bp deletion in exon8

Sanger Sequencing - Human TDRD7 knockout A549 cell line (AB267048)
  • Sanger seq

Unknown

Sanger Sequencing - Human TDRD7 knockout A549 cell line (AB267048)

Allele-2 : 1 bp deletion in exon 8.

Sanger Sequencing - Human TDRD7 knockout A549 cell line (AB267048)
  • Sanger seq

Unknown

Sanger Sequencing - Human TDRD7 knockout A549 cell line (AB267048)

Allele-3 : 2 bp insertion in exon 8.

Cell Culture - Human TDRD7 knockout A549 cell line (AB267048)
  • Cell Culture

Unknown

Cell Culture - Human TDRD7 knockout A549 cell line (AB267048)

Representative images of TDRD7 knockout A549 cells, low and high confluency examples (top left and right respectively) and wild-type A549 cells, low and high confluency (bottom left and right respectively) showing typical adherent, epithelial-like morphology. Images were captured at 10X magnification using a EVOS XL Core microscope.

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 8 and 2 bp deletion in exon 8 and 2 bp insertion in exon 8

Disease

Carcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab267048-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267048 Human TDRD7 knockout A549 cell line", "number":"AB267048-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255450 Human wild-type A549 cell line", "number":"AB267048-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab267048-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255450 Human wild-type A549 cell line", "number":"AB267048-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab267048 Human TDRD7 knockout A549 cell line", "number":"AB267048-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab267048-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267048 Human TDRD7 knockout A549 cell line", "number":"AB267048-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab267048-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267048 Human TDRD7 knockout A549 cell line", "number":"AB267048-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
TDRD7
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
  • Do not allow the cell density to exceed 7x104 cells/cm2.
Culture medium

F-12K + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

TDRD7 also known as Tudor Domain Containing 7 is a protein involved in RNA processing and regulation. It has a molecular weight of approximately 130 kilodaltons. Researchers have identified its expression largely in the testes eyes and brain. TDRD7 belongs to the Tudor domain-containing protein family and plays an important role in maintaining cellular RNA dynamics by interacting with various molecules in RNA-related processes.
Biological function summary

TDRD7 contributes to the formation and function of ribonucleoprotein (RNP) complexes needed for germ cell development and lens maturation. It actively participates in RNA granule assembly important for RNA stabilization and localization in cells. Through its Tudor domains TDRD7 binds symmetrically dimethylated arginines on other proteins recognizing and organizing these RNP complexes effectively.

Pathways

TDRD7 integrates into RNA regulatory pathways influencing processes such as mRNA splicing and degradation. It interacts with proteins like PIWIL1 and PIWIL2 which are involved in the piRNA pathway important for maintaining genomic integrity in germ cells. TDRD7 helps mediate gene expression regulation through these pathways impacting cellular functions and organismal development.

Mutations or dysregulation of TDRD7 are associated with congenital cataracts and other lens-related diseases. Moreover it has connections with gonadal development disorders due to its critical function in the testes. Disruptions in TDRD7 can link with proteins such as CRYAA and CRYBB2 important in maintaining the transparency and refractive properties of the lens leading to cataract formation when altered.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com